By Fineline Cube 
Denovo Biopharma, a US-headquartered precision medicine company with significant operations in China, announced a licensing agreement with Taiwan-headquartered Chuang Yi Global Asset Management Co., Ltd. (CYMD). Under the accord, CYMD secures exclusive development and commercialization rights to Denovo Bio’s biomarker-guided DB104 (liafensine) program in Taiwan, while Denovo Bio retains global rights outside the region.
Drug Profile
DB104 (liafensine) is an oral serotonin, norepinephrine, and dopamine reuptake inhibitor (SNDRI) and represents a first-in-class drug for treatment-resistant depression (TRD). Originally developed by AMRI and licensed to Bristol-Myers Squibb (BMS) in 2011, the drug demonstrated favorable tolerability in multiple clinical trials, with no discontinuations due to adverse events.
Acquisition and Development
Denovo Biopharma acquired global rights to liafensine in 2017, securing worldwide development, manufacturing, and commercialization rights. The company continues to advance the drug’s development globally, while CYMD will focus on its progress in Taiwan.-Fineline Info & Tech